Browsing Journal Articles (Medical School) by Subject "HIV"
Now showing items 1-5 of 5
-
Development of Phenotypic and Genotypic Resistance to Antiretroviral Therapy in the UNAIDS HIV Drug Access Initiative – Uganda
(Wolters Kluwer Health, Inc., 2003-07)Objective: We describe phenotypic drug resistance, response to therapy, and geno-typic mutations among HIV-infected patients in Uganda taking antiretroviral medica-tions for ≥ 90 days who had a viral load ≥ 1000 ... -
Effect of HIV-1 Infection on Malaria Treatment Outcome in Ugandan Patients
(MAKERERE UNIV, FAC MED , PO BOX 7072, KAMPALA, UGANDA, 2007-11-09)Background: Malaria and HIV-1 infection cause significant morbidity and mortality in sub-Saharan Africa. HIV-1 increases risk for malaria with the risk increasing as immunity declines.The effect of HIV-1 infection on ... -
Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience
(LIPPINCOTT WILLIAMS & WILKINS , TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, USA, PA, 19103, 2016)Background: Intensified tuberculosis (TB) case finding and isoniazid preventive therapy (IPT) are strongly recommended for children who are HIV infected. Data are needed to assess the feasibility of the WHO 2011 intensified ... -
Lopinavir Plus Nucleoside Reverse-transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-line Treatment of HIV (EARNEST): 144-week Follow-up Results From a Randomised Controlled Trial
(Elsevier, 2018-01)Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir ... -
Viral Load Detection Using Dried Blood Spots in a Cohort of HIV-1- Infected Children in Uganda: Correlations with Clinical and Immunological Criteria for Treatment Failure
(American Society for Microbiology, 2014-04-22)High rates of virological suppression were reported among HIV-1-infected children of low- and middle-income countries (LMIC) up to 5 to 6 years after receiving combined antiretroviral treatment (cART) (1). In 2013, the ...